Tnfrsf4-flox Mouse
一般名
Tnfrsf4-flox
製品ID
S-CKO-06496
背景情報
C57BL/6JCya
系統ID
CKOCMP-22163-Tnfrsf4-B6J-VA
状況
このマウス系統を論文で使用する場合は、「Tnfrsf4-flox Mouse（カタログ番号S-CKO-06496）はサイアジェンから購入しました。」と引用してください。
製品タイプ
年齢
遺伝子型
性別
数量
標準的な配送方法では、少なくとも3匹のヘテロ接合体キャリアを保証しています。ホモ接合体キャリアや指定された性別の個体の繁殖サービスも利用可能です。
基本情報
系統名
Tnfrsf4-flox
系統ID
CKOCMP-22163-Tnfrsf4-B6J-VA
遺伝子名
製品ID
S-CKO-06496
遺伝子別名
ACT35, CD134, Ly-70, Ox40, TXGP1L, Txgp1
遺伝子別名
C57BL/6JCya
遺伝子正式名称
tumor necrosis factor receptor superfamily, member 4
NCBI ID
修正
Conditional knockout
染色体
Chr 4
表現型
アプリケーション
--
さらに
系統詳細
EnsemblトランスクリプトID
ENSMUST00000030952
NCBIトランスクリプトID
NM_011659
ターゲット領域
Exon 3~4
有効領域の大きさ
~1.1 kb
遺伝子研究の概要
Tnfrsf4, also known as OX40 (CD134), is a member of the tumour necrosis factor receptor family and functions as a T cell co-stimulatory molecule [1]. It is activated by its cognate ligand OX40L (CD134L, CD252). The interactions of Tnfrsf4 and OX40L promote T cell survival, effector T cell phenotype, T cell memory, and increase effector cytokine production. This pathway is involved in multiple immunological pathways such as Th2, Th1, Th17 and Th22, and is critical for the expansion, differentiation, and survival of effector and memory T cells [1,7,9].
In various diseases, Tnfrsf4 has shown distinct impacts. In autoimmunity, the OX40-OX40L interaction has been proposed as a potential therapeutic target [1]. In nasopharyngeal carcinoma, TNFRSF4+ Treg cells might contribute to immune-suppression in the tumour microenvironment [2]. In thyroid-associated ophthalmopathy, increased activity of the TNFSF4/TNFRSF4 interaction was observed [3]. In chronic myeloid leukemia, Tnfrsf4-expressing Tregs promote immune escape of leukemia stem cells, and TNFRSF4 could be a potential target to boost antileukemic immunity [4]. In hepatocellular carcinoma, TNFRSF4 expression affects immune cell infiltration, gene mutation, and patient prognosis [5]. In esophageal squamous cell carcinoma, TNFRSF4+CD4+ Tregs with activated immunosuppressive function are enriched in post-treatment tumors from non-responders [6]. In non-M3 acute myeloid leukemia, elevated TNFRSF4 gene expression is a predictor of poor prognosis [8]. In atopic dermatitis, the expression of Tnfrsf4 and its ligand is increased, and targeting the OX40 pathway shows promise as a therapeutic approach [9].
In conclusion, Tnfrsf4 is a crucial T cell co-stimulatory molecule involved in multiple immunological processes. Its role in various diseases, such as autoimmunity, cancers, and inflammatory diseases, has been revealed through different research models. The study of Tnfrsf4 provides insights into disease mechanisms and potential therapeutic targets for these conditions.
References：
1. Webb, Gwilym J, Hirschfield, Gideon M, Lane, Peter J L. . OX40, OX40L and Autoimmunity: a Comprehensive Review. In Clinical reviews in allergy & immunology, 50, 312-32. doi:10.1007/s12016-015-8498-3. https://pubmed.ncbi.nlm.nih.gov/26215166/
2. Liu, Yang, He, Shuai, Wang, Xi-Liang, Zeng, Yi-Xin, Bei, Jin-Xin. 2021. Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution. In Nature communications, 12, 741. doi:10.1038/s41467-021-21043-4. https://pubmed.ncbi.nlm.nih.gov/33531485/
3. Li, Zhaohuai, Wang, Mei, Tan, Jia, Wang, Xianggui, Su, Wenru. 2022. Single-cell RNA sequencing depicts the local cell landscape in thyroid-associated ophthalmopathy. In Cell reports. Medicine, 3, 100699. doi:10.1016/j.xcrm.2022.100699. https://pubmed.ncbi.nlm.nih.gov/35896115/
4. Hinterbrandner, Magdalena, Rubino, Viviana, Stoll, Carina, Ochsenbein, Adrian F, Riether, Carsten. 2021. Tnfrsf4-expressing regulatory T cells promote immune escape of chronic myeloid leukemia stem cells. In JCI insight, 6, . doi:10.1172/jci.insight.151797. https://pubmed.ncbi.nlm.nih.gov/34727093/
5. Wang, Di, Hu, Huan, Ding, Huan, Tian, Feifei, Chi, Qingjia. . Elevated expression of TNFRSF4 impacts immune cell infiltration and gene mutation in hepatocellular carcinoma. In Cancer biomarkers : section A of Disease markers, 36, 147-159. doi:10.3233/CBM-210538. https://pubmed.ncbi.nlm.nih.gov/36591653/
6. Yang, Zhenlin, Tian, He, Chen, Xiaowei, Xue, Liyan, Gao, Shugeng. 2024. Single-cell sequencing reveals immune features of treatment response to neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma. In Nature communications, 15, 9097. doi:10.1038/s41467-024-52977-0. https://pubmed.ncbi.nlm.nih.gov/39438438/
7. Guttman-Yassky, Emma, Croft, Michael, Geng, Bob, Xing, Heming, Weidinger, Stephan. . The role of OX40 ligand/OX40 axis signalling in atopic dermatitis. In The British journal of dermatology, 191, 488-496. doi:10.1093/bjd/ljae230. https://pubmed.ncbi.nlm.nih.gov/38836560/
8. Gu, Siyu, Zi, Jie, Han, Qi, Song, Chunhua, Ge, Zheng. 2020. Elevated TNFRSF4 gene expression is a predictor of poor prognosis in non-M3 acute myeloid leukemia. In Cancer cell international, 20, 146. doi:10.1186/s12935-020-01213-y. https://pubmed.ncbi.nlm.nih.gov/32390761/
9. Croft, Michael, Esfandiari, Ehsanollah, Chong, Camilla, Wollenberg, Andreas, Guttman-Yassky, Emma. 2024. OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. In American journal of clinical dermatology, 25, 447-461. doi:10.1007/s40257-023-00838-9. https://pubmed.ncbi.nlm.nih.gov/38236520/
品質管理基準
精子検査
凍結前の精子濃度を測定し、精子の生存能力の判定します。
凍結後の精子では、各バッチから1本の凍結保存された精子を選び出し、体外受精に使用します。
環境基準:
SPF対応地域:
グローバル由来:
Cyagenお問い合わせ
カスタムの動物モデルに関するご相談は、下記のフォームにご記入いただき、ご連絡いただくか見積もりをご依頼ください。
Cyagenはお客様のプライバシーを大変重視しています。当社の最新の製品や情報をお届けしたいと思っています。お客様の設定をご確認ください。
これらの配信はいつでも解除できます。配信停止方法およびデータ保護の詳細は プライバシーポリシー をご確認ください。
以下のボタンをクリックすることで、このフォームにご入力いただいた個人情報をCyagenが保存・処理し、ご要望のコンテンツを提供することに同意されたことになります。